138 related articles for article (PubMed ID: 7298877)
1. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting.
Heim ME; Romer W; Queisser W
J Clin Pharmacol; 1981; 21(S1):86S-89S. PubMed ID: 7298877
[TBL] [Abstract][Full Text] [Related]
2. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.
Joss RA; Galeazzi RL; Bischoff A; Do DD; Goldhirsch A; Brunner KW
Cancer Chemother Pharmacol; 1982; 9(1):61-4. PubMed ID: 7139853
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
4. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
Heim ME; Queisser W; Altenburg HP
Cancer Chemother Pharmacol; 1984; 13(2):123-5. PubMed ID: 6467496
[TBL] [Abstract][Full Text] [Related]
5. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine.
Sheidler VR; Ettinger DS; Diasio RB; Enterline JP; Brown MD
J Clin Pharmacol; 1984 Apr; 24(4):155-9. PubMed ID: 6373843
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy.
Cronin CM; Sallan SE; Gelber R; Lucas VS; Laszlo J
J Clin Pharmacol; 1981; 21(S1):43S-50S. PubMed ID: 7028793
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of refractory cytostatic agent-induced vomiting with the synthetic cannabinoid levonantradol].
Heim ME; Queisser W
Onkologie; 1982 Apr; 5(2):94-6. PubMed ID: 7048169
[TBL] [Abstract][Full Text] [Related]
8. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.
Gerhartz HH; Binsack T; Hiller E
Klin Wochenschr; 1983 Jul; 61(14):719-21. PubMed ID: 6350696
[TBL] [Abstract][Full Text] [Related]
9. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
Stuart-Harris RC; Mooney CA; Smith IE
Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
[TBL] [Abstract][Full Text] [Related]
10. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration.
Laszlo J; Lucas VS; Hanson DC; Cronin CM; Sallan SE
J Clin Pharmacol; 1981; 21(S1):51S-56S. PubMed ID: 7298875
[TBL] [Abstract][Full Text] [Related]
11. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis.
Stambaugh JE; McAdams J; Vreeland F
J Clin Pharmacol; 1984; 24(11-12):480-5. PubMed ID: 6392353
[TBL] [Abstract][Full Text] [Related]
12. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations.
Diasio RB; Ettinger DS; Satterwhite BE
J Clin Pharmacol; 1981; 21(S1):81S-85S. PubMed ID: 7298876
[TBL] [Abstract][Full Text] [Related]
13. [Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's transl) clinical studies].
Higi M; Niederle N; Bremer K; Schmitt G; Schmidt CG; Seeber S
Dtsch Med Wochenschr; 1982 Aug; 107(33):1232-4. PubMed ID: 7049655
[No Abstract] [Full Text] [Related]
14. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
Hutcheon AW; Palmer JB; Soukop M; Cunningham D; McArdle C; Welsh J; Stuart F; Sangster G; Kaye S; Charlton D
Eur J Cancer Clin Oncol; 1983 Aug; 19(8):1087-90. PubMed ID: 6352278
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
Tramèr MR; Carroll D; Campbell FA; Reynolds DJ; Moore RA; McQuay HJ
BMJ; 2001 Jul; 323(7303):16-21. PubMed ID: 11440936
[TBL] [Abstract][Full Text] [Related]
16. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
17. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
18. [Prevention and control of chemotherapy-induced nausea and vomiting].
Gómez-Raposo C; Feliú-Batlle J; González-Baróna M
Med Clin (Barc); 2006 Feb; 126(4):143-51. PubMed ID: 16472500
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting. Easing patients' fear and discomfort with effective antiemetic regimens.
Bilgrami S; Fallon BG
Postgrad Med; 1993 Oct; 94(5):55-8, 62-4. PubMed ID: 8415336
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
